Hundreds of cystic fibrosis patients become eligible for ‘life-changing’ therapy - Some people with the rarest forms of the ...

Latest studies show Us pharma giant Vertex's new CF wonder pill Alyftrek has shown better results than their currently ...

Hundreds of children and adults with rare forms of cystic fibrosis in England will be able to access “life-changing” new ‘triple-combination’ therapy for the very first time, the NHS has announced.

Charles Kim Haskell told Newsweek he once thought he wouldn't live beyond his teenage years, but, at 31, he is enjoying his life.

This next-in-class triple combination treatment is licensed for people living with CF aged 6 years and older who have at least one F508del mutation or another responsive mutation in the cystic ...

A Ph.D. graduate student in biomolecular engineering at UC Santa Cruz, with a background in computer science and mathematics, ...

Dominion Energy is the kind of stable utility stock that's great to own during turbulent markets. Enbridge has a lower risk ...

Individuals with cystic fibrosis or CFTR gene variants have a 3-fold higher risk of developing pancreatic cancer after 50 years of age.

The FDA is expected to decide on treatments for bronchiectasis, chronic immune thrombocytopenia, fibromyalgia, Friedreich ataxia, and recurrent respiratory papillomatosis.

The number of advancements occurring in the medical community every year are astounding. For instance, there’s now ...

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for ALYFTREK® ...

BiomX has published promising phase 1b/2a trial results in Nature Communications, demonstrating that its phage cocktail BX004 ...